First half of 2011, as the market-style conversion, better growth of small plates, the GEM began underperformed the broader market, while the trend is less favorable than the pharmaceutical sector in Shanghai and Shenzhen 300 Index. Time into August,China digital thermometer because of the recent external China clinical thermometer uncertainties and worries about the future of the economy triggered sharp correction in A shares, but the pharmaceutical sector in this process has shown excellent resilience, such as Xinhua Medical (600,587), Tasly ( 600 535) and even in individual stock price hit a record high. The last two weeks from the medical section of the market performance, one of the chemical and pharmaceutical,China ear thermometer medical devices, medical services, medicine and commerce sub-sector turnover (turnover) are magnified.
This year,China digital blood pressure monitor the pharmaceutical sector will complete defense to an offensive turn. Determine the most fundamental basis is that we believe that investors are most China digital thermometer manufacturer concerned about the growth of pharmaceutical stocks has not changed. Medicare expansion so that pharmaceutical companies have a broader space for development; twice this year,China clinical thermometer manufacturer drug prices are mainly for individual pricing of foreign species for domestic enterprises to create a more level playing field; state of bio-pharmaceutical field the importance of innovation , so that pharmaceutical companies have to upgrade the power industry; you can see,China medical thermometer manufacturer the pharmaceutical industry to support the fundamental long-term growth factors (policy, social, demographic and other factors) remained strong, China rapid thermometer a group of outstanding enterprises are expected from the birth.
From the published reports from 2011, Tasly, Huahaiyaoye (600 521) and other good people listed companies are given a satisfactoryChina ear thermometer manufacturer answer; Guizhou Braun (002 424), Xinhua medical care, constant group (600 252) and other pre-degree increase in 100% or so; pharmaceutical sector has entered the 2011 price-earnings ratio of 27 times the attractive range. With the mid-year report released in stages, the growth of pharmaceutical companies will be listed once again been recognized.
Therefore, we think it is good medicine ushered in the middle plate configuration point. In the second half with a strong focus on innovative pharmaceutical companies, a strong R & D capability to help companies take the high ground of the tool industry, HRH medicine (600,276) and other listed companies in which the leader; followed by medical equipment sector, we view, which not only affected by the price reduction policy is small, while both the medical and precision equipment manufacturing dual properties, will benefit from the release of medical reform and the state medical needs the support of high-end equipment manufacturing, the proposed medical attention Xinhua (600,587 ); In addition, the active industrial upgrading, the pharmaceutical companies involved in international cooperation is the focus of our attention, such as Huahaiyaoye (600,521) As at present, there are seven formulations products, 10 bulk drug product by the U.S. FDA site certification; sea is Pharmaceutical (600 267) with global pharmaceutical giant Pfizer is a joint venture, co-production of high quality drugs; Chinese medicine sector in recent years, countries have to fully understand the career development of Chinese medicine to promote the importance and urgency of the cause of medicine increasing the support, in this context, the modern traditional Chinese medicine leading Tasly (600 535), and Tong Ren Tang (600 085) will usher in a good development opportunities. (The author Hualin Securities researcher)